In contrast, cytosine arabinoside (ara-C) and aphidicolin, which directly inhibit DNA synthesis, produced no significant increase in es expression. Thymidine (TdR), which is an allosteric inhibitor of ribonucleotide reductase that depletes dATP, dCTP and dGTP pools while repleting the dTTP pool, had no significant effect on es expression. These data suggest that surface expression of the es nucleoside transporter is regulated by a mechanism which is sensitive to the supply of deoxynucleotides. Because 5-FU (which specifically depletes dTTP pools) causes a large increase in expression whereas TdR (which depletes all precursors except dTTP) does not, this mechanism might be particularly sensitive to dTTP pools.
The salvage of preformed nucleosides requires their permeation across the plasma membrane and subsequent metabolic trapping by conversion to ribo-and deoxyribonucleotides. The efficiency of the nucleoside salvage pathway is believed to have major effects on sensitivity to a wide range of antimetabolite drugs. Modified nucleosides such as cytosine arabinoside (ara-C) and 2-chlorodeoxyadenosine are taken up by the salvage pathway, and low levels of activity are therefore a potential mechanism of drug resistance. In contrast the toxicity of agents that inhibit the de novo synthesis of DNA precursors, such as methotrexate and 5-fluorouracil (5-FU), can be reversed by uptake of thymidine from the extracellular fluid, so that increased nucleoside salvage capacity could result in treatment failure.
Preformed nucleosides enter mammalian cells via a number of nucleoside transport (NT) systems (Plagemann et al., 1988) . In mammalian cells, the equilibrative facilitated diffusion NT process (es) is widely distributed and sensitive to inhibition by S-(p-nitrobenzyl)-6-thioinosine (NBMPR) (Cass et al., 1974; Wiley et al., 1983; Belt et al., 1993) . In various cell types, es can be coexpressed with other different NT processes, such as the NBMPR-insensitive equilibrative NT (ei) (Belt, 1983; Crawford et al., 1990; Crawford and Belt, 1991) , or the Na + -linked concentrative NT process (cij) (Crawford et al., 1990; Crawford and Belt, 1991; Roden et al., 1991) . The es process is of high capacity and low affinity and is followed by phosphorylation by kinases with low capacity and high affinity for the nucleoside which enters the cell. Kinetic and computer analysis suggest that the transport of nucleosides is rate limiting at low (< 1IM) concentrations of extracellular nucleosides (Wiley et al., 1985; White et al., 1987) . Nucleoside levels of this order occur in human serum (Nottebrock and Then, 1977) , suggesting that nucleoside transporter expression might be an important rate-limiting step in the cellular utilisation of nucleosides by the salvage pathway in man.
Traditionally nucleoside transport and uptake have been studied using radiolabelled compounds. The J Pressacco et al and trypsin were purchased from Gibco (Grand Island, NY, USA). Plasticware was purchased from Falcon (Bedford, MA, USA).
Cell Culture
The human bladder cancer cell line, MGH-U1, the human acute lymphoblastic leukaemia cell line, CEM and the acute myeloid leukemia cell line, AML2 were maintained in aminimum essential media (a-MEM), and the acute lymphoblastic cell line, Jurkat, in RPMI-1640 medium. All media were supplemented with 0.01% streptomycin, 0.01% penicillin and 10% fetal calf serum (Whittaker, Walkersville, MD, USA and PA Biologicals, Sydney, Australia). The cells were grown at 37°C in a 5% carbon dioxide humidified atmosphere (Erlichman and Vidgen, 1984; Pressacco and Erlichman, 1993) and subcultured twice weekly until passage 20.
5-(SAENTA-x8)-fluorescein binding assay
Cells were resuspended at a concentration of 1 x 106ml-' in phenol red-free medium, and labelled with 5 nM 5-(SA-ENTA-x8)-fluorescein at room temperature (RT) for 10min in the dark, in the presence or absence of 2.5 iLM NBMPR as previously described (Jamieson et al., 1993 Dual staining with 5-(SAENTA-x8)-fluorescein and the vital DNA dye Hoechst-33342 enabled the investigation of changes in es expression throughout the cell cycle. Because competition was observed between Hoechst-33342 uptake and 5-(SAENTA-x8)-fluorescein binding, the concentration of Hoechst-33342 used was reduced from 10 to 1.0 iLM, and the concentration of 5-(SAENTA-x8)-fluorescein increased from 5 to 80 nM. Despite this relatively high 5-(SAENTA-x8)-fluorescein concentration, binding was shown to be specific as demonstrated by NBMPR displacement. As shown in Figure 1 , there was an increase in es expression during S-phase, which persisted into G2 phase.
Modulation of es expression was investigated using antimetabolite drugs with differing mechanisms of action. Each drug was used at a concentration that was growth inhibitory while maintaining cell viability as assessed by the laser light scattering pattern observed by flow cytometry. For the cytotoxic agents 5-FU and ara-C this corresponded approximately to the IC5o concentration as determined by clonogenic survival. The modulation of es expression on the surface of MGH-Ul cells by 5-FU, ara-C, TdR and APC following a 24 h exposure is shown in Figure 2 . Ara-C, TdR and APC had no appreciable effect on es expression, whereas 5-FU and hydroxyurea increased the expression of es, by up to 10-fold with 40 tLM 5-FU in MGH-U1 cells. The effects of hydroxyurea were further investigated using MGH-Ul, CEM, Jurkat, and AML2 cells (Figure 3) . In all of the cell lines, 24 h exposure to 50 and 200 tLM hydroxyurea increased es expression. This effect was reversed by simultaneous treatment with the protein translation inhibitor cycloheximide (2.5 tsg ml-'), indicating that the effect of hydroxyurea is to increase de novo synthesis of es, rather than to cause its redistribution in membranes. Treatment of CEM cells with 2.5 jig ml-' cycloheximide alone resulted in a decrease in es expression to 29% of control value at 24 h, and 6% of control at 48 h, giving a half-life of approximately 12 h for es on the cellular membrane.
Exponentially growing cells incubated in either nucleosidefree or nucleoside-rich media for 48 h showed no difference in es expression or modulation. Thus, preformed nucleosides did not alter the expression of es, consistent with the lack of modulation of es expression observed with TdR in our studies. Hydroxyurea concentration (gM) (Cabral et al., 1984; Wadler et al., 1987) and 5-FU (Grem and Fischer, 1989) , that inhibit the de novo synthesis of DNA precursors. Attempts have been made to exploit nucleoside salvage pathways in order to improve chemotherapy results. For example, potentiating the uptake and phosphorylation of ara-C by depleting the endogenous dCTP pool with hydroxyurea (Walsh et al., 1980; Rauscher and Cadman, 1983) or inhibiting these processes with agents such as dipyridamole to increase the effectiveness of MTX or 5-FU (Cabral et al., 1984; Wadler et al., 1987; Grem and Fischer, 1989) .
Discussion
In this paper we have confirmed that 5-(SAENTA-x8)-fluorescein is a high-affinity, specific ligand for es. Because we postulated that surface expression of nucleoside transporter might increase during DNA synthesis we examined its correlation with cell cycle distribution using dual labelling with 5-(SAENTA-x8)-fluorescein and the vital DNA dye Hoechst-33342. As shown in Figure 1 , 1979) . The comparatively small increase in es during the cell cycle argues against the expression being regulated to meet a demand for DNA precursors during S-phase. Using the protein synthesis inhibitor cycloheximide we obtained a half-life for es in the plasma membrane of 12 h. This agrees closely with the halflife of loss of nucleoside transport capacity observed during induced differentiation of HL60 cells (Chen et al., 1986) . If the synthesis of nucleoside transporter were indeed syn-. chronised with the onset of S-phase, as we had originally postulated, this comparatively long half-life might explain why the increase in es expression during the cell cycle is only approximately 2-fold. Expression of es can be modulated by treatment with growth-inhibitory concentrations of certain antimetabolites. Of particular interest is the increase in es expression following exposure to hydroxyurea, which inhibits ribonucleotide reductase and depletes deoxynucleotide triphosphate pools generally, and to 5-FU, which depletes dTTP. These increases were large compared to the natural increase in es expression during the cell cycle, and are therefore unlikely to be explained simply by a build up of cells in S-phase. Thymidine itself is an allosteric inhibitor of ribonucleotide reductase, and depletes dATP, dCTP and dGTP while increasing the dTTP pool, and treatment with this agent produced no increase in es expression. Aphidicolin and ara-C, which directly inhibit DNA synthesis, also had no significant effect on es expression.
We interpret these data as showing that cells can actively regulate the expression of es on the surface membrane, and that this regulation involves a feedback control which is sensitive to the supply of deoxynucleotides, particularly dTTP. It is well established that depletion of DNA precursors can increase the activity of salvage pathways, but this is usually considered to be due to an effect on the specific kinases which phosphorylate nucleosides, thereby trapping them inside the cell. Although it has been suggested that the efficiency of es is such that the initial rate of uptake is unlikely to be rate limiting for the salvage pathway, the large increases in es expression following exposure to 5-FU or hydroxyurea in vitro suggest that under some circumstances its capacity might be inadequate for maintenance of DNA synthesis. This up-regulation of es has important implications as a possible adaptive mechanism leading to antimetabolite drug resistance in cancer patients. Further studies should therefore be aimed at elucidating the mechanisms by which es expression is regulated in vitro and determining the relationship between the levels of expression and the response to chemotherapy in cancer patients. Because of the specificity and ease of use, flow cytometric measurement of fluorescent derivatives of SAENTA appears to offer a powerful new method for studying the role of es in response to antimetabolite drugs. ara-C, cytosine arabinoside; ara-CTP, ara-C triphosphate; 5-FU, 5-fluorouracil; TdR, thymidine; APC, aphidicolin: dTTP, thymidine-5'-triphosphate; dTMP, thymidine-5'-monophosphate, thymidylate; dATP, 2-deoxyadenosine-5'-triphosphate; dCTP, 2-deoxycytidine-5'-triphosphate; dGTP, 2-deoxyguanosine-5'-triphosphate.
